Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [10]. Core Insights - The report highlights that Eli Lilly's Q1 2025 revenue reached $12.729 billion, a 45% year-on-year increase, primarily driven by strong sales of tirzepatide, which contributed $6.15 billion, accounting for approximately 48% of Q1 revenue [5]. - The company maintains its full-year revenue guidance for 2025 at $58-61 billion but has lowered its adjusted EPS forecast to a range of $20.78 - $22.28, down from the previous $22.50 - $24.00 due to rising R&D costs and the impact of CVS Health's decision to remove Zepbound from its reimbursement list [6]. - Key catalysts for 2025 include data readouts for oral GLP-1 Orforglipron and Retatrutide, as well as various clinical trials for other drugs [8]. Sub-industry Ratings - Chemical Pharmaceuticals: No rating - Traditional Chinese Medicine: No rating - Biopharmaceuticals II: Neutral - Other Pharmaceuticals: Neutral [4]. Company Recommendations - The report does not provide specific buy or sell ratings for individual companies but emphasizes the overall performance of Eli Lilly in the context of its market position and product pipeline [4]. Financial Performance - Eli Lilly's R&D expenses were $2.73 billion, an 8% increase year-on-year, while SG&A expenses rose by 26% to $2.47 billion. The non-GAAP net profit was $3 billion, reflecting a 29% year-on-year growth, with earnings per share at $3.34, also up by 29% [5]. Research and Development Progress - The report notes successful progress in the development of oral GLP-1 and siRNA therapies, with significant advancements in oncology pipelines [7]. Future Focus - The report emphasizes the importance of monitoring the upcoming data readouts for oral GLP-1 and other key drugs in 2025, which could significantly impact the company's market position and financial performance [8].

Investment Rating - The overall industry investment rating is neutral, indicating that the expected return over the next six months is between -5% and 5% compared to the CSI 300 index [9]. Core Insights - The pharmaceutical sector showed a positive market performance with a gain of 0.90% on May 13, 2025, outperforming the CSI 300 index by 0.75 percentage points, ranking third among 31 sub-industries [3]. - Notable performances within the pharmaceutical sub-industries included hospitals (+1.82%), in vitro diagnostics (+1.17%), and medical devices (+1.12%), while offline pharmacies (-0.27%), vaccines (-0.21%), and blood products (+0.29%) lagged behind [3]. - Key individual stock performances included Huada Gene (+14.55%), Berry Genomics (+10.01%), and Dongfang Ocean (+10.00%) leading the gainers, while Yirui Biology (-5.91%), Sunshine Novo (-3.63%), and Zhengchuan Co. (-3.08%) were among the biggest losers [3]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceutical II: Neutral - Other pharmaceutical industries: Neutral [2]. Company Updates - BeiGene reported a 50.2% year-on-year increase in revenue for Q1 2025, reaching 8.048 billion yuan, with a net profit of -0.95 million yuan [4]. - Innovent Biologics announced a remarkable 129.92% year-on-year revenue growth for Q1 2025, totaling 381 million yuan, with a net profit of 17.97 million yuan [4]. - Guoyao Modern's subsidiary received approval for the injection of Amikacin Sulfate, passing the consistency evaluation for generic drug quality and efficacy [5]. - Zai Lab's application for a new drug for treating severe alopecia has been accepted by the National Medical Products Administration [5].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [13]. Core Views - The pharmaceutical sector experienced a decline of 0.84% on March 24, 2025, underperforming the CSI 300 index by 1.35 percentage points, ranking 21st among 31 sub-industries [5]. - Notable performances within sub-industries include vaccines (+0.17%) and medical research outsourcing (-0.16%), while hospitals (-2.17%) and medical devices (-1.35%) lagged [5]. - Alnylam's RNAi therapy Vutrisiran has received FDA approval for treating wild-type or hereditary ATTR-CM in adults, aimed at reducing cardiovascular mortality and hospitalizations [6]. Summary by Sections Market Performance - On March 24, 2025, the pharmaceutical sector's performance was -0.84%, underperforming the CSI 300 index by 1.35% [5]. - The top three gainers were Tianyu Co. (+9.95%), Zhongyuan Qihe (+8.82%), and Shanwaishan (+6.60%), while the largest decliners were Aipeng Medical (-10.22%), Innovation Medical (-9.97%), and Sanbo Brain Science (-8.99%) [5]. Industry News - Alnylam announced FDA approval for Vutrisiran, a subcutaneous RNAi therapy targeting specific mRNA to block the production of transthyretin protein, enhancing efficacy and metabolic stability [6]. - Garden Biologics reported a 13.58% year-on-year increase in revenue to 1.243 billion yuan for 2024, with a net profit growth of 60.76% to 309 million yuan [7]. - Shouxiangu reported a 10.87% decline in revenue to 699 million yuan for 2024, with a net profit decrease of 27.87% to 184 million yuan [7].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index within the next six months [10]. Core Insights - The pharmaceutical sector showed a performance increase of +0.86% on March 18, 2025, outperforming the CSI 300 index by 0.59 percentage points, ranking fourth among 31 sub-industries in the Shenwan classification [4]. - Avidity's investigational therapy, delpacibart zotadirsen (del-zota), demonstrated unprecedented efficacy in protein expression during its Phase 1/2 clinical trial, with significant increases in skeletal muscle delivery and protein generation [5]. - The report highlights the performance of various sub-sectors, with medical research outsourcing (+5.56%) and hospitals (+1.34%) leading, while medical devices (+0.09%) and vaccine sectors (+0.27%) lagged behind [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine production: No rating - Biopharmaceutical II: Neutral - Other pharmaceutical sectors: Neutral [3]. Recommended Companies and Ratings - The report does not specify individual company ratings but emphasizes the overall positive outlook for the pharmaceutical industry [3].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% in the next six months [11]. Core Insights - The pharmaceutical sector showed a slight increase of +0.02% on March 17, 2025, outperforming the CSI 300 Index by 0.26 percentage points, ranking 20th among 31 sub-industries [5]. - Notable performers within the pharmaceutical sub-industries included other biological products (+1.13%), blood products (+0.63%), and medical consumables (+0.34%), while hospitals (-1.28%), offline pharmacies (-1.04%), and medical devices (-0.53%) lagged [5]. - Geron announced the EU approval of its telomerase inhibitor Rytelo (imetelstat) for treating transfusion-dependent anemia in adult patients with myelodysplastic syndromes, marking a significant advancement in the industry [6]. Summary by Sections Market Performance - On March 17, 2025, the pharmaceutical sector's performance was +0.02%, outperforming the CSI 300 Index by 0.26 percentage points, with various sub-industries showing mixed results [5]. Industry News - Geron's Rytelo received EU approval as a monotherapy for treating transfusion-dependent anemia due to myelodysplastic syndromes, previously approved by the FDA in June 2024 [6]. Company News - WuXi AppTec reported a revenue of 39.241 billion yuan for 2024, a decrease of 2.73% year-on-year, with a net profit of 9.450 billion yuan, down 1.63% year-on-year [6]. - Dong-E E-Jiao announced a revenue of 5.921 billion yuan for 2024, an increase of 25.57% year-on-year, with a net profit of 1.557 billion yuan, up 35.29% year-on-year [6].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% over the next six months [11]. Core Insights - The pharmaceutical sector experienced a decline of 0.46% on March 13, 2025, underperforming the CSI 300 Index by 0.06 percentage points, ranking 15th among 31 sub-industries [5]. - Notable performers within the pharmaceutical sub-industries included offline pharmacies (+2.26%), pharmaceutical distribution (+1.07%), and blood products (+0.24%), while medical R&D outsourcing (-1.32%), hospitals (-1.17%), and medical consumables (-0.971%) lagged behind [5]. - The approval of BMS-986489 for clinical trials in China marks a significant development, as it is a combination of an anti-Fucosyl-GM1 monoclonal antibody and an anti-PD-1 monoclonal antibody, aimed at treating small cell lung cancer [6]. Market Performance - The report highlights that the pharmaceutical sector's performance is mixed, with specific companies like Saily Medical (+10.01%), Dezhan Health (+9.94%), and Dongfang Ocean (+9.84%) showing significant gains, while Zhejiang Medicine (-6.94%), Tianzhihang (-6.33%), and Berry Genomics (-6.12%) faced notable declines [5]. Company Updates - Baiyunshan reported a revenue of 74.993 billion yuan for 2024, a year-on-year decrease of 0.69%, with a net profit of 2.835 billion yuan, down 30.09% [6]. - Yahuang Pharmaceutical announced the completion of the first patient enrollment in a Phase I clinical trial for APL-2302, a USP1 inhibitor targeting advanced solid tumors [6]. - Tianshili received approval for clinical trials of NR-20201, a stem cell injection for treating acute ischemic stroke [7]. - Bai'ao Tai announced the acceptance of its application for marketing authorization of Golimumab injection, a biosimilar targeting TNF-α [7].

Investment Rating - The industry is rated as "Positive," with expectations of overall returns exceeding the CSI 300 Index by more than 5% over the next six months [11]. Core Insights - As of March 13, 2025, the pharmaceutical sector experienced a decline of 0.46%, underperforming the CSI 300 Index by 0.06 percentage points, ranking 15th among 31 sub-industries in the Shenwan classification [5]. - Notable performances within sub-industries include offline pharmacies (+2.26%), pharmaceutical distribution (+1.07%), and blood products (+0.24%), while medical R&D outsourcing (-1.32%), hospitals (-1.17%), and medical consumables (-0.971%) lagged behind [5]. - The approval of BMS-986489 for clinical trials in China marks a significant development, targeting small cell lung cancer patients, and is currently in Phase 3 clinical research internationally [6]. Summary by Sections Market Performance - The pharmaceutical sector's performance on March 13, 2025, was -0.46%, underperforming the CSI 300 Index [5]. - The top three gainers were Saily Medical (+10.01%), Dezhan Health (+9.94%), and Dongfang Ocean (+9.84%), while the top three losers were Zhejiang Medicine (-6.94%), Tianzhihang (-6.33%), and Berry Genomics (-6.12%) [5]. Industry News - The approval of BMS-986489, a combination of anti-Fucosyl-GM1 monoclonal antibody and anti-PD-1 monoclonal antibody, for clinical trials is a key highlight [6]. - Baiyunshan reported a revenue of 74.993 billion yuan in 2024, a decrease of 0.69% year-on-year, with a net profit decline of 30.09% [6]. - Yahui Pharmaceutical announced the completion of the first patient enrollment in a Phase I clinical trial for APL-2302, a USP1 inhibitor [6]. - Tianshili received approval for clinical trials of NR-20201 for treating acute ischemic stroke [7]. - Bai'ao Tai received a notice for the acceptance of its application for the marketing authorization of Golimumab injection, a biosimilar targeting TNF-α [7].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.96% on March 7, 2025, underperforming the CSI 300 Index by 0.65 percentage points, ranking 22nd among 31 sub-industries [4]. - The approval of ARS's Neffy (1 mg epinephrine nasal spray) by the FDA marks a significant innovation in the delivery method for treating type I allergic reactions in children aged 4 and above, representing the first major advancement in 35 years for this patient group [5][9]. - Notable stock performances included Aosaikang (+9.99%), Yipinhong (+9.77%), and Rejing Biology (+8.84%) on the gainers' list, while Aopumai (-6.26%), Puri Eye (-5.97%), and BGI (-4.86%) led the decliners [4]. Summary by Sections Market Performance - As of March 7, 2025, the pharmaceutical sector's performance was -0.96%, with sub-sectors like in vitro diagnostics (-0.43%) and blood products (-0.72%) performing better, while hospitals (-2.11%) and medical devices (-1.67%) lagged [4]. Industry News - The FDA's approval of Neffy is a pivotal development for the treatment of severe allergic reactions in children, highlighting the ongoing innovation in the pharmaceutical industry [5]. - Companies such as Jingxin Pharmaceutical announced an increase in their share repurchase plan, raising the total amount from a minimum of 200 million RMB to 350 million RMB [5]. - Nouvegen and BGI have entered a strategic cooperation agreement to leverage their respective expertise in reproductive genetics, tumor prevention, chronic disease management, and infection control [5]. Company News - Heng Rui Pharmaceutical received approval for clinical trials of several new drugs, indicating ongoing research and development efforts [6]. - Kanglong Chemical reported the completion of a share reduction plan, with a total of 10,666,716 shares reduced, representing 0.60% of the company's total share capital [6].

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [6]. Core Insights - Roche's innovative therapy TNKase has received FDA approval for the treatment of acute ischemic stroke (AIS), marking it as the first stroke medication approved in nearly 30 years [2][6]. - The pharmaceutical sector showed a performance increase of +0.54% on March 4, 2025, outperforming the CSI 300 index by 0.62 percentage points, ranking 19th among 31 sub-industries [1][6]. - Among sub-industries, in vitro diagnostics (+2.26%), medical devices (+1.17%), and hospitals (+0.85%) performed well, while other bioproducts (-0.06%), medical research outsourcing (+0.07%), and offline pharmacies (+0.17%) lagged [1]. Summary by Sections Market Performance - The pharmaceutical sector's performance on March 4, 2025, was +0.54%, outperforming the CSI 300 index by 0.62 percentage points, with in vitro diagnostics leading at +2.26% [1]. - Notable individual stock performances included BGI Genomics (+20.00%), Shengxiang Biology (+15.24%), and Aidi Pharmaceutical (+11.31%), while Jiangsu Wuzhong (-8.80%), Zhixiang Jintai (-6.22%), and Sihuan Bio (-6.01%) faced declines [1]. Company News - Yinos announced that its clinical immunohistochemistry laboratory received CAP certification, enhancing its clinical testing business prospects [2]. - Tiantan Biological reported that its human coagulation factor IX has completed clinical ethical review and is set to begin Phase III clinical trials, with cumulative R&D investment reaching 25.5766 million yuan [2]. - Sunshine Novo has repurchased 2.716789 million shares, accounting for 2.43% of its total share capital, with a total expenditure of approximately 99.75 million yuan [3]. - Tigermed has repurchased 9.8063 million shares, representing 1.1337% of its total share capital, with a total expenditure of approximately 500.12 million yuan [3].

2025 年 03 月 03 日 行业周报 看好/维持 医药 医药 礼来与 Magnet 达成近 13 亿美元分子胶合作 科伦药业（002422）：公司发布公告，公司 5%以上持股股东雅安国资 拟通过集中竞价的方式增持公司股份，拟增持金额为 5000-9900 万元，增 持价格不超过 37.60 元/股，资金来源为自有资金和股票回购专项贷款。 鱼跃医疗（002223）：公司发布公告，公司申请的自动体外除颤器（AED） 获得符合欧盟《医疗器械第 2017/745 号法规》（MDR）要求的 III 类医疗 器械 CE 认证证书，此次获批表明该产品具备欧盟市场的最新准入条件， 进一步提升了公司急救类产品在相应领域的综合竞争力。 昭衍新药（603127）：公司发布公告，公司累计通过集中竞价交易方 式回购 A 股股份 3,269,820 股，占公司总股份的 0.4363%，回购价格区间 为 13.20-18.15 元/股，使用资金总额为人民币 52,991,757.40 元（不含 交易费用）。 ◼ 走势比较 报告摘要 市场表现： 2025年3月3日，医药板块涨跌幅+0.66%，跑赢沪深300指数0.70pct， 涨跌幅 ...